Summary
Vertex Pharmaceuticals Incorporated (VRTX) filed a Form 8-K on April 26, 2012, to report its financial results for the quarter ended March 31, 2012. The primary purpose of this filing was to incorporate by reference a press release issued on the same date, which contained the company's detailed financial performance and operational updates for the period. Investors should note that this 8-K is essentially an announcement of the earnings release and does not contain new quantitative financial data directly within the form itself, other than referencing the attached press release. The press release (Exhibit 99.1) is the critical document for understanding VRTX's financial condition and results of operations for the first quarter of 2012. Any analysis of Vertex's performance for this period would necessitate a review of that accompanying press release.
Key Highlights
- 1Vertex Pharmaceuticals Inc. filed an 8-K on April 26, 2012.
- 2The filing announced the company's financial results for the quarter ended March 31, 2012.
- 3The press release containing the financial results for the quarter is incorporated by reference as Exhibit 99.1.
- 4The 8-K itself does not contain detailed financial statements, but directs investors to the press release for this information.
- 5This report serves as a formal notification of the earnings release to the SEC and the investing public.
- 6The information is presented as being furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).